OpenAlex
PricingAboutJobs
Log inGet started
Work

Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study

HTML

Year: 2008
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-07-4020
Authors: Mark R. Albertella, Paul M. Loadman, Philip H. Jones, Roger M. Phillips, Roy Rampling, Neil Burnet, Chris Alcock, Alan Anthoney, Egils Vjaters, Chris R. Dunk, Peter A. Harris, Alvin Wong, Alshad S. Lalani, Chris J. Twelves
Institutions: University of Bradford, Hutchison/MRC Research Centre, Medical Research Council, Beatson West of Scotland Cancer Centre, University of Cambridge, Addenbrooke's Hospital, John Radcliffe Hospital, University of Leeds, Cancer Research UK, St James's University Hospital, Pauls Stradiņš Clinical University Hospital
Language: English

Topic: Cancer therapeutics and mechanisms
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: AQ4N, bioreductive prodrugs, topoisomerase II inhibitors, tumor hypoxia, solid tumors, drug activation, tissue distribution, GLUT1, glioblastoma, bladder cancer, head and neck cancer, breast cancer, cervical cancer
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2155826289
FWCI: 2.628
Cites: 50
Cited by: 143
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security